| Previous close | 1.5500 |
| Open | 1.5500 |
| Bid | 1.2500 |
| Ask | 1.5500 |
| Strike | 15.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.5500 - 1.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 34 |
ZacksSAGE's Huntington's Disease Study Meets Primary Endpoint
The phase II SURVEYOR study evaluating SAGE's dalzanemdor as a potential treatment for patients with cognition dysfunction caused by Huntington's disease meets its primary endpoint.
Business WireSage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
CAMBRIDGE, Mass., June 11, 2024--Sage Therapeutics announced today topline results from the Phase 2 SURVEYOR Study. The study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo.
Business WireSage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 05, 2024--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 2:00 p.m. ET in Miami, FL.
